These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25341028)

  • 1. Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases.
    Dan D; Fischer R; Adler S; Förger F; Villiger PM
    Swiss Med Wkly; 2014; 144():w14030. PubMed ID: 25341028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe infections in patients with autoimmune diseases treated with cyclophosphamide.
    Cavallasca JA; Costa CA; Maliandi Mdel R; Contini LE; Fernandez de Carrera E; Musuruana JL
    Reumatol Clin; 2015; 11(4):221-3. PubMed ID: 25455720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide.
    Gurcan M; Esatoglu SN; Hamuryudan V; Saygin D; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Yurdakul S; Yazici H; Hatemi G
    Rheumatology (Oxford); 2020 Sep; 59(9):2264-2271. PubMed ID: 31840168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of oral cyclophosphamide in the treatment of giant cell arteritis.
    Quartuccio L; Maset M; De Maglio G; Pontarini E; Fabris M; Mansutti E; Mariuzzi L; Pizzolitto S; Beltrami CA; De Vita S
    Rheumatology (Oxford); 2012 Sep; 51(9):1677-86. PubMed ID: 22627726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.
    Fanouriakis A; Pamfil C; Sidiropoulos P; Damian L; Flestea A; Gusetu G; Rednic S; Bertsias G; Boumpas DT
    Lupus; 2016 May; 25(6):627-36. PubMed ID: 26692040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.
    Kanzler S; Gerken G; Dienes HP; Meyer zum Büschenfelde KH; Lohse AW
    Z Gastroenterol; 1997 Jul; 35(7):571-8. PubMed ID: 9273991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR;
    Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single-center retrospective study.
    Li J; Dai G; Zhang Z
    Clin Rheumatol; 2015 Feb; 34(2):273-8. PubMed ID: 25053381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.
    Munyangango EM; Le Roux-Villet C; Doan S; Pascal F; Soued I; Alexandre M; Heller M; Lièvre N; Aucouturier F; Caux F; Laroche L; Prost-Squarcioni C
    Br J Dermatol; 2013 Feb; 168(2):381-90. PubMed ID: 22963186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
    Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
    J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using cyclophosphamide in inflammatory rheumatic diseases.
    Brummaier T; Pohanka E; Studnicka-Benke A; Pieringer H
    Eur J Intern Med; 2013 Oct; 24(7):590-6. PubMed ID: 23528932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
    de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
    Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids.
    de Seze J; Delalande S; Fauchais AL; Hachulla E; Stojkovic T; Ferriby D; Hatron PY; Vermersch P
    J Rheumatol; 2006 Apr; 33(4):709-11. PubMed ID: 16583474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe infections in plasmapheresis-treated systemic lupus erythematosus.
    Aringer M; Smolen JS; Graninger WB
    Arthritis Rheum; 1998 Mar; 41(3):414-20. PubMed ID: 9506568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.